Genflow Biosciences Share Discussion Threads

[moneymunch] 29/4/2024 17:34

Yes indeed Northeast, 2p plus and more on its way, Final Results expected soon and every chance Eric will have an update or two on proceedings. Excitement building!!! Gl :-)

[northeast14] 29/4/2024 16:19

Great day again today! Someone is keen to buy everything

[moneymunch] 29/4/2024 14:13

Share accumulation in progress!!! Gla :-)

[moneymunch] 28/4/2024 20:06

Looking forward to the Merry month of May!!! Gla holders, a significant re-rate beckons imho.....On and UP!!! :-)

[moneymunch] 27/4/2024 21:00

Patents in the pipeline, and more to come. Gla ;-)

.4338267

VARIANTS OF SIRT6 FOR USE IN PREVENTING AND/OR TREATING AGE-RELATED DISEASES

EP - 20.03.2024

Int.Class H02K 7/18

Appl.No 22808414

Applicant UNIV ROCHESTER

Inventor GORBUNOVA VERA

The present invention relates to an isolated nucleic acid molecule encoding a variant of sirtuin 6 (SIRT6) having at least 75% identity with sequence SEQ ID NO: 1, the variant having at least one mutation selected in the group comprising or consisting of a N308K substitution and a A313S substitution with respect to sequence SEQ ID NO: 1.

The invention provides means for the regulation of ageing, and/or senescence, and/or lifespan in an individual.

The invention further provides means for the repair of double strand breaks in a cell.

Finally, the invention also provides means for the prevention and/or the treatment of an age-related disease.

.........


20230018934

METHOD OF IN VIVO ADMINISTRATION OF THE CODING SEQUENCE OF THE SIRT6 GENE VIA ADENO-ASSOCIATED VIRUS

US - 19.01.2023

Int.Class A61K 48/00

Appl.No 17865688

Applicant GENFLOW BIOSCIENCES SRL

Inventor Eric LEIRE

Methods for in vivo administration of the coding sequence of the sirt6 gene. In particular, methods that include the administration of adeno-associated virus vectors or recombinant adeno-associated virus vectors including the coding sequence of the sirt6 gene.

[northeast14] 27/4/2024 20:22

Really appreciate you sharing that. Any slight leak of a big Pharma will send this

[prashaprash] 27/4/2024 19:47

Being doctor myself working in same field of Liver problems- I can tell you if this research trial is a success then potential will be huge with patent!At the moment 20-25% with NASH gets into advanced fibrosis of liver and it is silent ,slow disease! Overweight population and specially with metabolic syndrome HighBMI, diabetes, hypertension they are at high risk.NASH is Number 1 in uk for liver transplant...

[northeast14] 27/4/2024 17:44

The only thing is we can’t include the grants from this year or the money from the raise. I don’t think the year end results matter. As now we know there’s cash in the bank and money to last the projects for 3 years. GLA

[marmiesz] 27/4/2024 10:28

Managed to top up more at 1.60 earlier this week. This is a very long term hold for me. I like the way Eric manages the company and the vision he has. The pipeline has amazing potential and the range of collaborations is impressive. No debt and a good financial runway. I'd say there is about £3.5M cash if we include the grants.I wouldn't be surprised if there was more news on that front and news from the US in the next 6 months. Marmie

[cyberbub] 26/4/2024 14:27

Well as you suggest, just look at what happened last year when they announced a collaboration with Rochester, trebled in a couple of days :-)No advice intended of course.

[moneymunch] 26/4/2024 14:01

A very nice 650k buy just in at 1.9p!!! Gla :-)

[northeast14] 26/4/2024 13:46

Yes year end was this time last year. Thought they might release early again.

[moneymunch] 26/4/2024 13:34

News on patents, progress on pipeline, US investors, collaborators etc at anytime, but we're still awaiting Final reports from the 4 invivo studies to be officially published, which could be highly significant, although not sure if they're already in the mix as we progress to human clinical trials, or if there's going to be a peer-review or similar scientific publication, but Vera's podcast is well worth a listen as she goes into great depth of the studies they're carrying out on Sirt6, and interestingly enough, Vera hasn't published any news at all from her lab, so far this year???.Gla :-)


September 2023



The Company is conducting in-vivo evaluations of its centenarian SIRT6 gene therapy in four different NASH mice models in conjunction with four leading partners in the field: The University of Liverpool, UK, The University of Rochester, US, the International Clinical Research Center (FNUSA-ICRC) , Czech Republic and Physiogenex, France.

These studies have been wide reaching and have included the analysation of over 700 mice, with the intention of understanding the efficacy and safety of the Company's drug candidate in animal models with NASH and has generated essential information in preparation for clinical trials in humans. Final reports are expected by the end of 2023.

........

A fascinating and insightful Podcast interview with Vera Gorbunova from 24/10/23 discussing the promising potential for Sirt6 and how she is conducting indepth research in collaboration with Biotech companies, and confirms results should be available in a few months. Gla :-)

SIRT6 The Science Behind The Longevity Gene | Professor Vera Gorbunova Ep1

Oct. 24, 2023

[cyberbub] 26/4/2024 13:13

Northeast, GENF have until 30 June to release their final results (ie 6 months after the end of their financial year). They did release them in late April last year though. IMO the strength over the last couple of days might be something else eg the US patent?

[moneymunch] 26/4/2024 12:24

Not long now before sub 2p will be a distant memory with any luck, a major re-rate or two highly likely with plenty of significant positive newsflow stacking UP!!! Gla :-)

[moneymunch] 26/4/2024 10:27

Looking good and strong, very low free float with the majority of shares held tightly for greater things to come and so any good news should see a solid and significant re-rate. Gla holders, Momentum building, Genflow is all set for a stellar year ahead imho. ;-)

[northeast14] 25/4/2024 21:00

Nice one! I’m sure you won’t be disappointed

[prashaprash] 25/4/2024 20:42

Got 1.2 millions shares recently

[northeast14] 25/4/2024 20:22

I’m sure all this will come before end of play Tuesday when I think they need to RNS the year end by. I’m sure Eric will have something up his sleeve as he never disappoints

[cyberbub] 25/4/2024 15:16

The results are likely to make mediocre reading financially of course. The important thing will be a corporate and clinical update... Plus confirmation of cash reserves/runway...

[moneymunch] 25/4/2024 11:54

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,585 followers

23m

🧬 Genflow Biosciences has an updated presentation! 🧬

To learn more about the cutting-edge #biotech research & studies currently underway, as well as Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s strong investment thesis, click here:

#SIRT6 #GENF #NASH #aging #healthspan

[moneymunch] 25/4/2024 06:19

Let's hope so Northeast, in the meantime the Final Results must be due in the next few days, which should make good reading. Gl ;-)

[northeast14] 24/4/2024 20:07

You just get the impression something big is brewing and could be released any day

[moneymunch] 24/4/2024 05:47

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,585 followers
18h

Safety paramount in the #biotech industry, and at Genflow Biosciences (LON:GENF) (OTCQB:GENFF), it's our top priority. We're proud to have developed patent-pending technology to enhance safety in our #SIRT6 studies.

It is this unwavering commitment to safety that has allowed us to advance a number of our studies to the pre-clinical/development stage, including treatments for diseases ranging Werner Syndrome to #NASH.

Learn more about Genflow's innovative studies & exciting investment thesis:

#GENF #aging #healthspan #NASH #genetherapy
Investors – Genflow Bioscience

[moneymunch] 23/4/2024 20:41

Cutting edge science with patents pending, compelling preclinical data progressing to human clinical trials, prestigious academic partners and a leading influential and distinguished hands on Scientific Advisory Board, at least c£4m plus cash in the bank and a market cap of £4.5m.

Exponential upside potential and prospects!!!

Will a Major Pharma/JV partner wait for positive trial results from Genflow's Nash Human Clinical Phase 1/2 trials planned for next year, or will one move early given how hot the Nash/Liver space is right now, as well as the promise of a rapidly expanding and evolving longevity market and the compelling nature of SIRT6's profound importance and influence over multiple disease targets associated with aging.

Exciting times!!! Gla holders :-)